Application of XCT790 in preparation of medicine for treating calcified aortic valve diseases

A technology of XCT790, 1.XCT790, applied in the application field of XCT790 in the preparation of drugs for the treatment of calcific aortic valve disease, to achieve the effect of improving osteogenic differentiation in vitro

Inactive Publication Date: 2020-08-21
ZHEJIANG UNIV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is currently no effective drug for the treatment of CAVD, and valve replacement has become the only treatment, but valve replacement has its own limitations. Therefore, it is more and more important to explore the specific pathogenesis of CAVD and find suitable targets for early intervention. urgent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of XCT790 in preparation of medicine for treating calcified aortic valve diseases
  • Application of XCT790 in preparation of medicine for treating calcified aortic valve diseases
  • Application of XCT790 in preparation of medicine for treating calcified aortic valve diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] 1. Take the aortic valve tissue from the heart transplant recipient, store it in sterile PBS, and quickly transport it back to the laboratory with an ice box. On the primary cell laboratory, wash the valve with pre-cooled sterile PBS to remove residual Blood clot until the valve leaflets are white, the whole process should be strictly aseptic and the time between valve isolation and cell culture should be shortened as much as possible; the cleaned valve tissue should be placed in a solution containing penicillin (1000U / ml) and streptomycin ( 1000U / ml) in sterile PBS for 10-15 minutes.

[0025] 2. Weigh 100mg type II collagenase powder (purchased from Sigma-Aldrich, USA), suspend and dissolve in 50ml sterile PBS buffer, prepare 2% type II collagenase digestion solution, and then filter with 0.22um Net filter to remove bacteria in the digestive enzyme working solution and prevent cell contamination.

[0026] 3. Put the valve tissue into a 15ml sterile centrifuge tube, ad...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of XCT790 in preparation of a medicine for treating calcified aortic valve diseases and a culture method for inhibiting valve stromal cells from differentiating into osteoblasts. In an osteogenesis-induced in-vitro calcification model, it is shown that XCT790 can inhibit valve interstitial cells from being converted into osteoblasts, and it is proved that the XCT790 plays a role in protection by up-regulating antioxidant protein Hmox1. The beneficial effects of the present invention are mainly reflected in that: application of XCT790 in preparation of the medicine for treating calcified aortic valve diseases is provided, and the method for remarkably improving in-vitro osteogenic differentiation of valve interstitial cells after XCT790 treatment is provided, so that a new medicine choice is provided for calcified aortic valve diseases.

Description

[0001] (1) Technical field [0002] The invention relates to the application of XCT790 in the preparation of medicine for treating calcific aortic valve disease, and a culture method for inhibiting the differentiation of valve interstitial cells to osteoblasts. [0003] (2) Background technology [0004] Calcific aortic valve disease (CAVD) is a progressive disease of the aortic valve, mainly manifested as fibrous hyperplasia and calcification of the valve leaflets leading to hardening of the valve, and in severe cases, aortic valve stenosis may occur, causing Left ventricular outflow tract obstruction. In developed countries, the incidence of CAVD is about 2% in people over 65 years old and about 4% in people over 85 years old. In the past, it was believed that CAVD is a passive degenerative change, which is a process in which the valve degenerates and hardens due to the deposition with age; however, basic research in recent years has shown that CAVD lesions involve endotheli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/433A61P9/00C12N5/077
CPCA61K31/433A61P9/00C12N5/0654C12N2500/35C12N2500/38C12N2501/30C12N2501/999C12N2506/13
Inventor 胡王兴王建安刘先宝
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap